C57BL/6 mice were subcutaneously injected with 1 × 106 B16-F10 tumor cells or 5 × 105 MC38 tumor cells; BALB/c mice were subcutaneously injected with 4 × 105 4T1 tumor cells; and NPG mice were subcutaneously injected with 1 × 106 Raji cells. Tumor cells were suspended in 100 μl of phosphate-buffered saline (PBS) buffer and injected into the flank. B16-F10, MC38, 4T1, and Raji tumors were allowed to grow in mice for approximately 10, 7, 7, and 25 days, respectively. Tumor sizes were calculated as follows: volume = 0.5 × length × width2. When tumor sizes became approximately 100 mm3, mice were anesthetized with pentobarbital (80 mg/kg) and locally irradiated using the Varian Trilogy Stereotactic System with a single dose of 20 Gy.
Trilogy stereotactic system
Manufactured by Agilent Technologies
The Trilogy Stereotactic System is a precision instrument designed for accurate positioning and stabilization of samples or specimens during scientific analysis or experimentation. It provides a stable and adjustable platform to securely hold and orient samples, enabling consistent and repeatable measurements or observations.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using trilogy stereotactic system
1
Tumor Induction and Radiation Therapy in Mouse Models
2
Comprehensive Tumor Immunotherapy Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Female C57BL/6 mice aged 6–8 weeks were purchased from the Center of Experimental Animals of the Third Military Medical Univercity (TMMU). Nude mice were purchased from VitalStar Biotechnology Co. Ltd. (Beijing, China). The mouse handling protocols were approved by the Institutional Animal Care and Use Committee of TMMU. To establish tumor models, B16F10 cells (2 × 105 in 100 µL of PBS) were subcutaneously inoculated into the right flank of 6–8-week-old female C57BL/6 mice or nude mice. When the tumors became palpable, tumor volume was monitored twice per week. In immunotherapeutic models, 2 × 105 B16F10 cells were subcutaneously inoculated into the right flank of 6–8-week-old female C57BL/6 mice. Mice received 200 µg of intraperitoneal anti-PD-L1 monoclonal antibody (10F.9G2, Be0101, BioXcell) or the equivalent isotype control antibody (BioXcell, BE0090) on days 4, 7, and 10.
For radiation-combined immunotherapeutic models, 2 × 105 B16F10 cells were subcutaneously inoculated into the right legs of C57BL/6 mice. When the tumors reached approximately 50 mm3, the mice were locally irradiated using the Varian Trilogy Stereotactic System at a single dose of 20 Gy. On the same day, 200 µg of anti-PD-1 monoclonal antibody (10F.9G2, Be0101, BioXcell) or equivalent isotype control antibody (BioXcell, BE0090) was injected intraperitoneally every three days three times.
For radiation-combined immunotherapeutic models, 2 × 105 B16F10 cells were subcutaneously inoculated into the right legs of C57BL/6 mice. When the tumors reached approximately 50 mm3, the mice were locally irradiated using the Varian Trilogy Stereotactic System at a single dose of 20 Gy. On the same day, 200 µg of anti-PD-1 monoclonal antibody (10F.9G2, Be0101, BioXcell) or equivalent isotype control antibody (BioXcell, BE0090) was injected intraperitoneally every three days three times.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!